Concord Drugs Hits New 52-Week High of Rs. 71.25, Up 88.89%

Concord Drugs has reached a significant milestone by hitting a new 52-week high of Rs. 71.25 today, October 13, 2025. This achievement marks a notable performance for the microcap pharmaceutical and biotechnology company, especially as it has outperformed its sector by 3.15%. Over the past two days, Concord Drugs has shown a consecutive gain, rising by 4.88%, indicating a positive trend in its stock performance.
The stock's intraday high of Rs. 71.25 reflects a 4.84% increase, showcasing its strong momentum. Additionally, Concord Drugs is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, further emphasizing its robust market position.

In contrast, the broader market has experienced some fluctuations, with the Sensex opening lower at 82,049.16 and currently trading at 82,243.74, down by 0.31%. Despite this, Concord Drugs has demonstrated impressive growth over the past year, with a remarkable 88.89% increase compared to the Sensex's modest 1.05% performance. The stock's previous 52-week low was Rs. 26.1, highlighting its substantial recovery and growth trajectory.